Biological
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2005 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
National Cancer Institute (NCI) (2) · Michael Morse, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 3
- Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)CompletedPhase 1National Cancer Institute (NCI)NCT00217373Written as Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
- Vaccine Therapy in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1Michael Morse, MDNCT00027534Written as TRICOM-CEA(6D)
- Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT00052351Written as recombinant fowlpox-CEA(6D)/TRICOM vaccine
Given in every arm · 4 — Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine is usual care beside what is tested
- Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT00088933Written as recombinant fowlpox-CEA(6D)/TRICOM vaccine
- Vaccine Therapy With or Without Sargramostim in Treating Patients With CancerTerminatedPhase 1National Cancer Institute (NCI)NCT00009958Written as recombinant fowlpox-CEA(6D)/TRICOM vaccine
- Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedPhase 1National Cancer Institute (NCI)NCT00028496Written as recombinant fowlpox-CEA(6D)/TRICOM vaccine
- Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic CancerCompletedPhase 1H. Kim LyerlyNCT00128622Written as recombinant fowlpox-CEA(6D)/TRICOM vaccine